A Phase II Study of Axitinib in Advanced Carcinoid Tumors: Preliminary Results Abstract #1179

Introduction: NETs are highly vascularized neoplasms overexpressing VEGF as well as VEGFR. Axitinib is a TKI with selective picomolar potency against VEGFR-1, -2 and -3
Aim(s): To evaluate the safety and efficacy of axitinib in patients with advanced carcinoid tumors
Materials and methods: We performed a phase II trial of axitinib 5 mg BID in patients with advanced low to intermediate grade carcinoid tumors. Prior antiangiogenic therapy with a dedicated VEGF pathway inhibitor was not permitted. The primary endpoints were PFS and 1-year PFS rate
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Mauro Cives

To read results and conclusion, please login ...

Further abstracts you may be interested in

#299 Clinical and Immunohistochemical Evaluation of Medullary Thyroid Cancer (MTC) and C Cell Hyperplasia (CCH)
Introduction: MTC and CCH has a variable clinical presentation and prognosis and no data are available on the correlation between immunoistochemical (IIC) characterization and clinical behavior.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Prof Laura De Marinis
Authors: Lugli F, Fusco A, Bianchi A, Milardi D, ...
#211 Phase II Study of Sunitinib Following Hepatic Transarterial Embolization for Metastatic Neuroendocrine Tumors
Introduction: Hepatic transarterial embolization is often recommended for patients with liver-predominant metastatic NETs. Antiangiogenic therapy following embolization may delay tumor revascularization.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
#214 Comparison of the AJCC and ENETS Staging Classifications for Neuroendocrine Tumors of the Pancreas
Introduction: The AJCC Cancer Staging Manual (7th edition, 2010) has introduced a novel TNM staging classification for pancreatic NETs. This classification has not yet been validated.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
Authors: Strosberg J, Cheema A, Weber J, Kvols L, ...
#217 Risk of Metastatic Spread in Patients with Early-Stage, Surgically Resected Pancreatic Neuroendocrine Tumors
Introduction: The risk of metastatic spread among patients with early-stage surgically resected pancreatic neuroendocrine tumors has not been well-established.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
Authors: Strosberg J, Cheema A, Weber J, Kvols L, ...
#321 Role of VEGFR-2, P53, P53R2 and Ki-67 Expression in Metastatic Carcinoid Cancer
Introduction: Ki-67 expression is a well-known prognostic factor in neuroendocrine tumors. The role of modified expression of p53, p53R2 and VEGFR2 in this disease’s liver metastases has not been established.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Ranyell Matheus Spencer
Authors: Spencer R, Costa W, Salvador H, Diniz A, ...
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.